Thalidomide therapy for low-risk Myelodysplasia

被引：12

作者：

Bowen, D ^{[1
]}

Macllwaine, L ^{[1
]}

Cavanagh, J ^{[1
]}

Killick, S ^{[1
]}

Culligan, D ^{[1
]}

Thomson, E ^{[1
]}

Mufti, G ^{[1
]}

机构：

[1] Ninewells Hosp, Dept Haematol, Dundee DD1 9SY, Scotland

来源：

LEUKEMIA RESEARCH | 2005年 / 29卷 / 02期

关键词：

D O I：

10.1016/j.leukres.2004.05.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：235 / 236

页数：2

共 4 条

[1]

Cheson BD, 2000, BLOOD, V96, P3671

[2] Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes [J].

Raza, A ;

Meyer, P ;

Dutt, D ;

Zorat, F ;

Lisak, L ;

Nascimben, F ;

du Randt, M ;

Kaspar, C ;

Goldberg, C ;

Loew, J ;

Dar, S ;

Gezer, S ;

Venugopal, P ;

Zeldis, J .

BLOOD, 2001, 98 (04) :958-965

[3] Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome [J].

Strupp, C ;

Hildebrandt, B ;

Germing, U ;

Haas, R ;

Gattermann, N .

LEUKEMIA, 2003, 17 (06) :1200-1202

[4] Thalidomide for the treatment of patients with myelodysplastic syndromes [J].

Strupp, C ;

Germing, U ;

Aivado, M ;

Misgeld, E ;

Haas, R ;

Gattermann, N .

LEUKEMIA, 2002, 16 (01) :1-6

← 1 →